Early iron reduction programme for thalassaemia patients after bone marrow transplantation
Open Access
- 1 March 2000
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 25 (6), 653-656
- https://doi.org/10.1038/sj.bmt.1702212
Abstract
Thirty thalassaemia patients received iron reduction starting at around 3 months post transplant. Sixteen received desferrioxamine and nine had phlebotomy, five patients had desferrioxamine followed by phlebotomy. The desferrioxamine group had higher serum ferritin levels at the start of iron reduction as compared to the phlebotomy group (5292 vs 2453 μg/l, P EQ 0.001). After 444 and 407 days of iron reduction, serum ferritins at cessation of iron reduction in both groups was similar (665 vs 588 μg/l). The rate of decline of serum ferritin in both groups was similar. There was no graft rejection during the programme. Early institution of iron reduction in ex-thalassaemia is safe. Bone Marrow Transplantation (2000) 25, 653–656.Keywords
This publication has 10 references indexed in Scilit:
- Busulphan level and early mortality in thalassaemia patients after BMTBone Marrow Transplantation, 1999
- Phlebotomy to Reduce Iron Overload in Patients Cured of Thalassemia by Bone Marrow TransplantationBlood, 1997
- Desferrioxamine therapy accelerates clearance of iron deposits after bone marrow transplantation for thalassaemiaBritish Journal of Haematology, 1995
- Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsiesBritish Journal of Haematology, 1995
- Survival in Medically Treated Patients with Homozygous β-ThalassemiaNew England Journal of Medicine, 1994
- Bone marrow transplantation in thalassemia: modifications of hepatic iron overload and associated lesions after long‐term engraftingLiver International, 1994
- Fate of iron stores in thalassaemia after bone-marrow transplantationThe Lancet, 1993
- Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia majorAmerican Journal of Hematology, 1993
- Bone Marrow Transplantation in Patients with ThalassemiaNew England Journal of Medicine, 1990
- Adriamycin cardiomyopathy—risk factorsCancer, 1977